NHWA released its performance for the first half of the year, with a net profit attributable to the parent company of 700 million yuan, an increase of 11.38%

NHWA released its semi-annual report for 2025, with operating revenue of 3.01 billion yuan, a year-on-year increase of 8.93%; net profit attributable to the parent company was 700 million yuan, a year-on-year increase of 11.38%. The net profit excluding non-recurring gains and losses was 699 million yuan, an increase of 10.33%. The basic earnings per share were 0.69 yuan. The company has over 70 research projects underway, with research funding of 395 million yuan, an increase of 23.97%. In terms of innovative drug research and development, among the 17 projects under research, 1 has completed phase III clinical trials, and 2 have completed phase II clinical trials. In the field of generic drugs, 48 projects are underway, with 1 production approval obtained